In this Issue
Chief Medical Editor's Page
By Allen C. Ho, MD Chief Medical Editor and Robert L. Avery, MD Associate Medical Editor
Perspectives: From the Editors of New Retina MD
Will the noble objectives of this law set up a roadblock to innovation?
By Richard S. Kaiser, MD; and Jonathan L. Prenner, MD
Business of Retina
Pennsylvania Avenue Updates
Meaningful use must be demonstrated to earn Medicare incentive payments.
By Jeremy D. Wolfe, MD
By David Boyer, MD; Matthew Benz, MD; and Alexander Eaton, MD
Part 2 of 2 parts. Dealing with companies and taking your idea to market.
By Nikolas J.S. London, MD; Andre J. Witkin, MD; and Alok S. Bansal, MD with Emmett T. Cunningham Jr., MD, PHD, MPH; Paul E. Tornambe, MD; and Eugene De Juan Jr., MD
A minimally invasive, straightforward rescue technique.
By Nicole Siegel, MD; Steven Ness, MD; and Vasiliki Poulaki, MD, PHD
Individualized plans may be warranted, as the disease course can vary.
By Won Ki Lee, MD
By John W. Kitchens, MD
By Timothy V, Johnson, MD; Swathi Kaliki, MD; and Carol L. Shields, MD
The VIEW 1 and 2 studies showed high degrees of safety and efficacy at 2 years.
By Jeffery S. Heier, MD
By Philip J. Rosenfeld, MD, PHD
How the study results have affected my treatment approach for AMD.
By Rohit Ross Lakhanpal, MD, FACS
By Glenn J. Jaffe, MD and James D. Palmer, MD
By Pravin U. Dugel, MD
The extended-release device alone provided clinically and statistically significant improvement in central retinal thickness.
By Michael A. Singer, MD
Preventing apoptosis may not be enough to prevent cell death.
By Demetrios G. Vavvas, MD, PHD
A new study suggests that nutritional supplements may have the potenial to enhance the effect of anti-VEGF agents plus photodynamic therapy or laser.
By R. Joseph Olk, MD
By Keith A. Warren, MD
Individualized therapy is crucial to good patient outcomes.